Måndag 29 Juni | 18:35:19 Europe / Stockholm
Est. tid*
2027-06-10 07:15 Bokslutskommuniké 2027
2027-03-04 07:15 Kvartalsrapport 2027-Q3
2026-12-03 07:15 Kvartalsrapport 2027-Q2
2026-09-09 N/A X-dag ordinarie utdelning INTEG B 0.00 SEK
2026-09-03 07:15 Kvartalsrapport 2027-Q1
2026-06-04 - Bokslutskommuniké 2026
2026-03-05 - Kvartalsrapport 2026-Q3
2025-11-21 - Kvartalsrapport 2026-Q2
2025-11-10 - Extra Bolagsstämma 2025
2025-10-29 - Årsstämma
2025-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2025-09-01 - Kvartalsrapport 2026-Q1
2025-06-03 - Bokslutskommuniké 2025
2025-03-03 - Kvartalsrapport 2025-Q3
2024-12-04 - Kvartalsrapport 2025-Q2
2024-09-26 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2024-09-25 - Årsstämma
2024-08-29 - Kvartalsrapport 2025-Q1
2024-05-30 - Bokslutskommuniké 2024
2024-02-29 - Kvartalsrapport 2024-Q3
2023-12-04 - Kvartalsrapport 2024-Q2
2023-10-04 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 - Årsstämma
2023-08-31 - Kvartalsrapport 2024-Q1
2023-06-08 - Bokslutskommuniké 2023
2023-03-01 - Kvartalsrapport 2023-Q3
2022-12-01 - Kvartalsrapport 2023-Q2
2022-10-03 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 - Årsstämma
2022-08-31 - Kvartalsrapport 2023-Q1
2022-06-10 - Bokslutskommuniké 2022
2022-03-02 - Kvartalsrapport 2022-Q3
2021-12-02 - Kvartalsrapport 2022-Q2
2021-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 - Kvartalsrapport 2022-Q1
2021-05-31 - Bokslutskommuniké 2021
2021-03-03 - Kvartalsrapport 2021-Q3
2020-12-02 - Kvartalsrapport 2021-Q2
2020-09-30 - Årsstämma
2020-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 - Kvartalsrapport 2021-Q1
2020-06-08 - Bokslutskommuniké 2020
2020-04-20 - Extra Bolagsstämma 2020
2020-03-02 - Kvartalsrapport 2020-Q3
2019-12-02 - Kvartalsrapport 2020-Q2
2019-09-30 - Årsstämma
2019-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 - Kvartalsrapport 2020-Q1
2019-06-10 - Bokslutskommuniké 2019
2019-03-04 - Kvartalsrapport 2019-Q3
2018-12-17 - Kvartalsrapport 2019-Q2
2018-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 - Årsstämma
2018-09-24 - Kvartalsrapport 2019-Q1
2018-06-25 - Bokslutskommuniké 2018
2018-03-26 - Kvartalsrapport 2018-Q3
2017-12-18 - Kvartalsrapport 2018-Q2
2017-09-25 - Årsstämma
2017-09-25 - Kvartalsrapport 2018-Q1
2017-06-30 - Bokslutskommuniké 2017
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Bolaget utvecklar system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Ukraine's Ministry of Health submits proposal to the government on expanded use of osseointegration in healthcare

2026-06-29 08:30:00

Mölndal, Sweden, 29 June 2026 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces that Ukraine's Ministry of Health (MOZ) has completed the preparatory phase of the proposal to introduce osseointegration as part of the national treatment of amputees. The proposal is now being forwarded to the Cabinet of Ministers for a government decision.

In early 2026, the Ukrainian government adopted a roadmap to reform the country's infrastructure for prosthetic treatment. At a high-level coordination meeting in April, attended by the Minister of Health, the Minister of Social Policy and the head of the National Health Service of Ukraine (NSZU), among others, a working group was established to prepare the pilot project and gather opinions from the relevant consultation bodies on the matter. The assessment now presented marks the conclusion of the working group's preparatory work, in which the consultation bodies' opinions have been reviewed and processed. The agency is now submitting the basis for the decision to the government's secretariat for further preparation. The government is expected to be in a position to decide on the financial and executive structure of the project.

"The decision by Ukraine's Ministry of Health to advance the proposal to make osseointegration part of Ukraine's public healthcare toward a binding government decision is very positive. It strengthens the recognition of the method as an established treatment and may, over time, give more amputees access to care with the OPRA® Implant System. We continue to follow the process closely and stand ready to support the country's healthcare providers and patients," says Martin Hillsten, CEO of Integrum.

Integrum's OPRA® has been used in approximately 100 osseointegration procedures in Ukraine since 2023. The company has established Centers of Excellence in Kyiv and Cherkasy; Dr Rickard Brånemark has been central to building the company's presence in the country and continues to support the clinical training of the country's surgeons; and in April 2026 the company recruited a business manager to coordinate its operations in the country. A state-funded pilot project would expand Integrum's addressable market and contribute to broader recognition of osseointegration as an established treatment method.

For background, read the interview with Victoria Boiko, Business Development Lead, at Integrum Investor News.